United Therapeutics Corp at JPMorgan Healthcare Conference Transcript
Great. Good afternoon, everyone. My name is Jess Fye, large-cap biotech analyst at JP Morgan, and we're continuing the 44th Annual JPMorgan Healthcare Conference today with United Therapeutics.
I'm joined up here by the company's Chair and CEO, Dr. Martine Rothblatt, who's going to give a presentation on the business, then we're going to go into some Q&A. If you're in the room and you want to ask a question, just raise your hand, and then I'll bring you a microphone. (Operator Instructions)
So with that, let me turn it over to Martine.
Thank you, Jess. Thanks, Jess, and thanks, everybody at JPMorgan for coming to the presentation. I'm going to show quite a few slides today and say a lot of words. But I think if you leave here with just two words, you will understand United Therapeutics completely. And those two words are IPF, that's one word --IPF.
And the second word is super-prostacyclin,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
